Loading
Loading
India's First AI Studio for Biotech
Combining high-throughput technologies, artificial intelligence, and liquid biopsy to make early cancer detection accurate, accessible, and non-invasive.
Who We Are
Prakirbha AI Diagnostics is committed to delivering a game-changing experience in cancer diagnosis and treatment strategies. We believe that early detection saves lives — and that AI can make it happen.
We are building India's first AI Studio dedicated to biotechnology and biomedical innovation, working at the intersection of machine learning, deep learning, and life sciences.
Our work applies high-throughput technologies in combination with liquid biopsy to make early detection possible, accurate, and non-invasive — transforming how cancer is found and fought.
To make the diagnosis of cancer at an early stage a reality using accurate, AI-enabled diagnostic solutions with strategized and effective treatments.
How It Works
A simple blood draw captures circulating biomarkers — no surgery needed.
Our ML & deep learning models analyze biomarker patterns with 99.2% accuracy.
Actionable results delivered fast — enabling treatment before cancer progresses.
Our Approach
We combine the cutting edge of molecular biology with the power of artificial intelligence to create diagnostic solutions that are more accurate, earlier, and less invasive than anything before.
Non-invasive blood-based testing detecting cancer biomarkers without surgical procedures. Making diagnostics accessible and repeatable at scale.
State-of-the-art AI models trained to identify patterns in blood-based biomarker data, enabling highly accurate early-stage cancer detection.
Processing large volumes of biological data rapidly, allowing identification of biomarker signatures previously impossible to detect.
Our flagship research identifies blood-based biomarkers for breast cancer using advanced machine learning and deep learning methodologies.
Research & Innovation
Our research has received support through prestigious programs — NIDHI PRAYAS and MeitY grants — validating both the scientific merit and societal impact of our work.
A provisional patent has been filed for our blood-based biomarker identification methodology, cementing our pioneering position in AI-driven cancer diagnostics.
Our Journey
Prakirbha AI Diagnostics established with a vision to revolutionize cancer detection through AI.
Received government backing through the prestigious NIDHI PRAYAS program, validating our research direction.
Secured MeitY funding and filed provisional patent for our blood-based biomarker identification methodology.
5+ AI models trained with 99.2% accuracy. Expanding AI approaches to other biomedical challenges.
Questions
Liquid biopsy is a non-invasive test that detects cancer biomarkers from a simple blood sample. Unlike traditional biopsies that require tissue removal through surgery, liquid biopsy analyzes circulating tumor DNA, proteins, and other markers — making early detection safer, faster, and repeatable.
Our AI models are trained on large datasets of blood-based biomarker data. They identify subtle patterns that human analysis might miss, enabling detection at much earlier stages. Our models achieve 99.2% accuracy on test datasets, significantly outperforming traditional diagnostic methods.
We are currently in the research and development phase. Our technology is being validated through rigorous testing and we are working toward clinical trials. Our goal is to make this technology accessible to patients in the near future through partnerships with healthcare providers.
Our current research focuses on breast cancer biomarker detection. However, the underlying AI methodology is designed to be extensible — we are actively working on expanding to other cancer types including lung, colorectal, and pancreatic cancer.
We welcome collaborations with research institutions, hospitals, biotech companies, and AI researchers. Whether you have relevant datasets, clinical expertise, or AI capabilities, we'd love to explore how we can work together. Use the contact form below to reach out.
Let's Work Together
We are expanding to solve other biomedical and biotechnology challenges using AI-driven approaches. If you're working on an interesting problem, we'd love to connect.
Get In Touch
Whether you're a researcher, clinician, or investor — we'd love to hear from you.